Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population

T cells play an important role in antitumor immunity, and molecules regulating T-cell activity could influence cancer susceptibility. The distinct role of coinhibitory receptors in immunosurveillance has been considered. B- and T-lymphocyte attenuator (BTLA) is one of these receptors, which negatively regulate immune responses. The aim of this study was to investigate the association between BTLA gene polymorphisms and susceptibility to renal cell carcinoma (RCC) in the Polish population.

Altogether 282 patients with RCC and 480 healthy subjects were genotyped for the following polymorphisms: rs2705511, rs1982809, rs9288952, rs16859633, rs9288953, rs2705535, and rs1844089 using the TaqManSNP Genotyping Assays.

Here, we found that the presence of rs1982809G allele (genotype GG+AG) is associated with increased risk of RCC (odds ratio = 1.38; 95% CI: 1.03-1.86; P = 0.03). In patients with clear-cell RCC (ccRCC) with high-grade (3 and 4) tumors, the frequency of rs1982809[GG] genotype was significantly higher as compared to those with low-grade (1 and 2) tumors and to the controls (0.14 vs. 0.06, P = 0.05 and 0.14 vs. 0.06, P = 0.04, respectively). Moreover, we have noticed the trend for overrepresentation of carriers of rs2705511C allele in patients with RCC as compared with the controls (0.51 vs. 0.44, P = 0.08) Haplotype rs2705511C/rs1982809G/rs9288952A/rs9288953T/rs2705535C/rs1844089G (CGATCG) increased the risk of RCC of 46% (odds ratio = 1.46; 95% CI: 1.08-1.96; Pcorrected = 0.05).

Our results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies.

Urologic oncology. 2016 May 24 [Epub ahead of print]

Anna Partyka, Krzysztof Tupikowski, Anna Kolodziej, Romuald Zdrojowy, Agnieszka Halon, Bartosz Malkiewicz, Janusz Dembowski, Irena Frydecka, Lidia Karabon

Department of Experimental Therapy, L. Hirszfeld Institute of Immunology & Experimental Therapy, Wroclaw, Poland., Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland., Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Experimental Therapy, L. Hirszfeld Institute of Immunology & Experimental Therapy, Wroclaw, Poland., Department of Experimental Therapy, L. Hirszfeld Institute of Immunology & Experimental Therapy, Wroclaw, Poland; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe